ALESSANDRO GONCALVES CAMPOLINA
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
- Health Economic Evaluations of Cancer in Brazil: A Systematic Review(2018) CAMPOLINA, Alessandro G.; YUBA, Tania Y.; DECIMONI, Tassia C.; LEANDRO, Roseli; DIZ, Maria del Pilar Estevez; NOVAES, Hillegonda M. D.; SOAREZ, Patricia C. deBackground: A large number of health economic evaluation (HEE) studies have been published in developed countries. However, Brazilian HEE literature in oncology has not been studied. Objective: To investigate whether the scientific literature has provided a set of HEE in oncology capable of supporting decision making in the Brazilian context. Methods: A systematic review was conducted to identify and characterize studies in this field. We searched multiple databases selecting partial and full HEE studies in oncology (1998-2013). Results: Fifty-five articles were reviewed, of these, 33 (60%) were full health economic evaluations. Type of cancers most frequently studied were: breast (38.2%), cervical (14.6%), lung (10.9%) and colorectal (9.1%). Procedures (47.3%) were the technologies most frequently evaluated. In terms of the intended purposes of the technologies, most (63.6%) were treatments. The majority of the incremental cost-effectiveness ratios (ICERs) reported have been below the cost-effectiveness threshold suggested by the World Health Organization (WHO). Conclusions: There has been an increase in the number of HEEs related to cancer in Brazil. These studies may support decision-making processes regarding the coverage of and reimbursement of healthcare technologies for cancer treatment in Brazil.
conferenceObject SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN CANCEROLOGY IN BRAZIL BETWEEN 1980 AND 2013(2014) YUBA, T. Y.; DECIMONI, T. C.; LEANDRO, R.; CAMPOLINA, A. G.; SOAREZ, P.conferenceObject ECONOMIC ANALYSIS OF HEPATO CELLULAR CARCINOMA TREATMENT BY SEVERITY OF DISEASE(2017) TANI, J. A.; CAMPOLINA, A. G.; DECIMONI, T. C.; TOMITAO, M.; FERREIRA, L. A.conferenceObject RESOURCE UTILIZATION AND TREATMENT OF PATIENT WITH HEPATOCELULLAR CARCINOMA - A MICROCOSTING ANALYSIS(2017) TANI, J. A.; DECIMONI, T. C.; FERREIRA, L. A.; TOMITAO, M.; CAMPOLINA, A. G.conferenceObject HOW DOES HIGH MELD SCORE INCREASES TOTAL EXPENDITURE ON HEALTH SYSTEM? A MICRO-COSTING PROSPECTIVE COHORT STUDY(2017) TURRI, J. A.; FERREIRA, L. A.; DECIMONI, T. C.; CAMPOLINA, A. G.- Higher MELD score increases the overall cost on the waiting list for liver transplantation: a micro-costing analysis based study(2017) TURRI, Jose Antonio Orellana; DECIMONI, Tassia Cristina; FERREIRA, Leandro Augusto; DINIZ, Marcio Augusto; HADDAD, Luciana Bertocco de Paiva; CAMPOLINA, Alessandro GonçalvesABSTRACT BACKGROUND: The pre-transplant period is complex and includes lots of procedures. The severity of liver disease predisposes to a high number of hospitalizations and high costs procedures. Economic evaluation studies are important tools to handle costs on the waiting list for liver transplantation. OBJECTIVE: The objective of the present study was to evaluate the total cost of the patient on the waiting list for liver transplantation and the main resources related to higher costs. METHODS: A cost study in a cohort of 482 patients registered on waiting list for liver transplantation was carried out. In 24 months follow-up, we evaluated all costs of materials, medicines, consultations, procedures, hospital admissions, laboratorial tests and image exams, hemocomponents replacements, and nutrition. The total amount of each resource or component used was aggregated and multiplied by the unitary cost, and thus individual cost for each patient was obtained. RESULTS: The total expenditure of the 482 patients was US$ 6,064,986.51. Outpatient and impatient costs correspond to 32.4% of total cost (US$ 1,965,045.52) and 67.6% (US$ 4,099,940.99) respectively. Main cost drivers in outpatient were: medicines (44.31%), laboratorial tests and image exams (31.68%). Main cost drivers regarding hospitalizations were: medicines (35.20%), bed use in ward and ICU (26.38%) and laboratorial tests (13.72%). Patients with MELD score between 25-30 were the most expensive on the waiting list (US$ 16,686.74 ± 16,105.02) and the less expensive were those with MELD below 17 (US$ 5,703.22 ± 9,318.68). CONCLUSION: Total costs on the waiting list for liver transplantation increased according to the patient’s severity. Individually, hospitalizations, hemocomponents reposition and hepatocellular carcinoma treatment were the main cost drivers to the patient on the waiting list. The longer the waiting time, the higher the total cost on list, causing greater impact on health systems.
- Many Miles to Go: A Systematic Review of the State of Cost-Utility Analyses in Brazil(2017) CAMPOLINA, Alessandro G.; ROZMAN, Luciana M.; DECIMONI, Tassia C.; LEANDRO, Roseli; NOVAES, Hillegonda M. D.; SOAREZ, Patricia Coelho DeBackground Little is known about the quality and quantity of cost-utility analyses (CUAs) in Brazil. Objective The objective of this study was to provide a systematic review of published CUAs of healthcare technologies in Brazil. Methods We performed a systematic review of economic evaluations studies published in MEDLINE, EMBASE, LILACS (Latin American and Caribbean Health Sciences Literature), SciELO (Scientific Electronic Library Online), NHS EED (National Health Service Economic Evaluation Database), HTA (Health Technology Assessment) Database, Web of Science, Scopus, Bireme (Biblioteca Regional de Medicina), BVS ECOS (Health Economics database of the Brazilian Virtual Library of Health), and SISREBRATS (Sistema de Informacao da Rede Brasileira de Avaliacao de Tecnologias em Saude [Brazilian Network for the Evaluation of Health Technologies]) from 1980 to 2013. Articles were included if they were CUAs according to the classification devised by Drummond et al. Two independent reviewers screened articles for relevance and carried out data extraction. Disagreements were resolved through discussion or through consultation with a third reviewer. We performed a qualitative narrative synthesis. Results Of the 535 health economic evaluations (HEEs) relating to Brazil, only 40 were CUAs and therefore included in the analysis. Most studies adhered to methodological guidelines for quality of reporting and 77.5% used quality-adjusted life-years (QALYs) as the health outcome. Of these studies, 51.6% did not report the population used to elicit preferences for outcomes and 45.2% used a specific population such as expert opinion. The preference elicitation method was not reported in 58.1% of these studies. The majority (80.6%) of studies did not report the instrument used to derive health state valuations and no publication reported whether tariffs (or preference weights) were national or international. No study mentioned the methodology used to estimate QALYs. Conclusions Many published Brazilian cost-utility studies adhere to key recommended general methods for HEE; however, the use of QALY calculations is far from being the current international standard. Development of health preferences research can contribute to quality improvement of health technology assessment reports in Brazil.